Augmenting Chemosensitivity of Malignant Melanoma Tumors via Proteasome Inhibition

Melanoma poses a great challenge to patients, oncologists, and biologists because of its nearly universal resistance to chemotherapy. Many studies have shown that nuclear factor κB is constitutively activated in melanoma, thereby promoting the proliferation of melanoma cells by inhibiting the apoptotic responses to chemotherapy. Nuclear factor κB activity is regulated by phosphorylation and subsequent degradation of inhibitor of nuclear factor κB by the ubiquitin-proteasome pathway. In this study, we show that the novel proteasome inhibitor, bortezomib, inhibited the growth of melanoma cells in vitro at a concentration range of 0.1–10 nm and in combination with the chemotherapeutic agent temozolomide, the inhibitory effect on melanoma cell growth was even more prominent. Data from a murine model showed reduced tumor growth when bortezomib was administered to human melanoma tumors. Strikingly, animals receiving bortezomib in combination with temozolomide achieved complete remission of palpable tumors after only 30 days of therapy, lasting >200 days. Our data indicate strongly that bortezomib in combination with chemotherapeutic agents should be studied additionally for the treatment of melanoma.

[1]  P. Elliott,et al.  Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  M. Karin,et al.  Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation , 1996, Molecular and cellular biology.

[3]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Bucana,et al.  Nuclear factor-kappaB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  Jürgen R. Müller,et al.  Lymphotoxin beta receptor induces sequential activation of distinct NF-kappa B factors via separate signaling pathways. , 2003, The Journal of biological chemistry.

[6]  G. Mills,et al.  Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-κB signaling , 2002, Oncogene.

[7]  Douglas B. Evans,et al.  The Nuclear Factor-κB RelA Transcription Factor Is Constitutively Activated in Human Pancreatic Adenocarcinoma Cells , 1999 .

[8]  G. Sledge,et al.  Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth , 1997, Molecular and cellular biology.

[9]  C. Logothetis,et al.  Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. , 2003, Molecular cancer therapeutics.

[10]  J. Cusack,et al.  Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB , 1999, Nature Medicine.

[11]  M. Herlyn,et al.  Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[12]  A. E. Rogers,et al.  Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. , 1997, The Journal of clinical investigation.

[13]  J. Manfredi,et al.  Multiple roles of the tumor suppressor p53 , 2002, Current opinion in oncology.

[14]  C. Y. Wang,et al.  NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. , 1998, Science.

[15]  J. Adams.  Potential for proteasome inhibition in the treatment of cancer. , 2003, Drug discovery today.

[16]  L. Deng,et al.  2-Acetylaminofluorene Up-regulates Rat mdr1bExpression through Generating Reactive Oxygen Species That Activate NF-κB Pathway* , 2001, The Journal of Biological Chemistry.

[17]  J. Tschopp,et al.  NF-κB Signals Induce the Expression of c-FLIP , 2001, Molecular and Cellular Biology.

[18]  T. Yeh,et al.  Expression of Bcl-2 Family Modulated Through p53-Dependent Pathway in Human Hepatocellular Carcinoma , 2003, Digestive Diseases and Sciences.

[19]  A. Eggermont,et al.  Adjuvant interferon-alpha for melanoma revisited: news from old and new studies. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  A. Baldwin,et al.  THE NF-κB AND IκB PROTEINS: New Discoveries and Insights , 1996 .

[21]  S. Ruben,et al.  I kappa B interacts with the nuclear localization sequences of the subunits of NF-kappa B: a mechanism for cytoplasmic retention. , 1992, Genes & development.

[22]  Z. Ronai,et al.  Death receptors and melanoma resistance to apoptosis , 2003, Oncogene.

[23]  M. Weinstock.  Issues in the epidemiology of melanoma. , 1998, Hematology/oncology clinics of North America.

[24]  P. Dhawan,et al.  A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells. , 2002, The Journal of biological chemistry.

[25]  S. Makarov.  NF-κB as a therapeutic target in chronic inflammation: recent advances , 2000 .

[26]  Petr Pancoska,et al.  p53 has a direct apoptogenic role at the mitochondria. , 2003, Molecular cell.

[27]  P. Dhawan,et al.  Correction: A Novel NF-κB-inducing Kinase-MAPK Signaling Pathway Up-regulates NF-κB Activity in Melanoma Cells , 2001, The Journal of Biological Chemistry.

[28]  A. Richmond,et al.  Enhanced Degradation of I-κBα Contributes to Endogenous Activation of NF-κB in Hs294T Melanoma Cells , 1997 .

[29]  M. Bar‐eli,et al.  Transcriptional regulation of metastasis-related genes in human melanoma , 2004, Clinical & Experimental Metastasis.

[30]  A. Richmond,et al.  Enhanced degradation of I-kappaB alpha contributes to endogenous activation of NF-kappaB in Hs294T melanoma cells. , 1997, Cancer research.

[31]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[32]  J. Adams.  Development of the proteasome inhibitor PS-341. , 2002, The oncologist.

[33]  S. Makarov.  NF-kappaB as a therapeutic target in chronic inflammation: recent advances. , 2000, Molecular medicine today.

[34]  J C Reed,et al.  IAPs block apoptotic events induced by caspase‐8 and cytochrome c by direct inhibition of distinct caspases , 1998, The EMBO journal.

[35]  Richard Pazdur,et al.  Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. , 2003, The oncologist.

[36]  Z. Ronai,et al.  p53-Mdm2--the affair that never ends. , 2002, Carcinogenesis.

[37]  V. Castronovo,et al.  The NF-kappa B transcription factor and cancer: high expression of NF-kappa B- and I kappa B-related proteins in tumor cell lines. , 1994, Biochemical pharmacology.

[38]  H. Nakshatri,et al.  Transformation of interleukin-3-dependent cells without participation of Stat5/bcl-xL: cooperation of akt with raf/erk leads to p65 nuclear factor kappaB-mediated antiapoptosis involving c-IAP2. , 2001, Blood.

[39]  P. Dhawan,et al.  Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. , 2002, Cancer research.

[40]  C. Jongeneel,et al.  Efficient adenoviral transfer of NF‐κB inhibitor sensitizes melanoma to tumor necrosis factor‐mediated apoptosis , 1999, International journal of cancer.

[41]  J. Adams.  Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. , 2002, Current opinion in chemical biology.

[42]  D. Green,et al.  The Lymphotoxin-β Receptor Induces Different Patterns of Gene Expression via Two NF-κB Pathways , 2002 .

[43]  Wei Yang,et al.  MGSA/GRO-mediated melanocyte transformation involves induction of Ras expression , 2000, Oncogene.

[44]  A. Baldwin,et al.  The NF-kappa B and I kappa B proteins: new discoveries and insights. , 1996, Annual review of immunology.

[45]  H. Lenz.  Clinical update: proteasome inhibitors in solid tumors. , 2003, Cancer treatment reviews.

[46]  L. Schuchter,et al.  Metastatic melanoma , 2001, Current treatment options in oncology.

[47]  Z Chen,et al.  Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  Z. Ronai,et al.  Role of TRAF2/GCK in melanoma sensitivity to UV-induced apoptosis , 2000, Oncogene.

[49]  C. Van Waes,et al.  Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. , 1999, Cancer research.

[50]  V. Castronovo,et al.  Highly-expressed p100/p52 (NFKB2) sequesters other NF-kappa B-related proteins in the cytoplasm of human breast cancer cells. , 1995, Oncogene.

[51]  P. Elliott,et al.  Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  E. Abraham.  NF-kappaB activation. , 2000, Critical care medicine.

[53]  G. Dong,et al.  Expression of a Dominant-Negative Mutant Inhibitor-κBα of Nuclear Factor-κB in Human Head and Neck Squamous Cell Carcinoma Inhibits Survival, Proinflammatory Cytokine Expression, and Tumor Growth in Vivo , 1999 .

[54]  Martin F. Mihm,et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  C. Harris,et al.  Distinct pattern of p53 phosphorylation in human tumors , 2001, Oncogene.

[56]  Jürgen R. Müller,et al.  Lymphotoxin β Receptor Induces Sequential Activation of Distinct NF-κB Factors via Separate Signaling Pathways* , 2003, The Journal of Biological Chemistry.

[57]  P. Elliott,et al.  26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer , 2001, Journal of cellular biochemistry.

[58]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[59]  C. Bucana,et al.  Nuclear Factor-κB Activity Correlates with Growth, Angiogenesis, and Metastasis of Human Melanoma Cells in Nude Mice , 2000 .

[60]  D. Green,et al.  The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. , 2002, Immunity.